For research use only. Not for therapeutic Use.
GSK 366 is a potent kynurenine-3-monooxygenase (KMO) inhibitor with IC50s of 2.3 nM and 0.7 nM for human KMO and P. fluorescens-KMO (Pf-KMO), respectively[1].
| Catalog Number | I019047 |
| CAS Number | 1953157-39-5 |
| Synonyms | 3-[5-chloro-6-[(1R)-1-(6-methylpyridazin-3-yl)ethoxy]-1,2-benzoxazol-3-yl]propanoic acid |
| Molecular Formula | C17H16ClN3O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H16ClN3O4/c1-9-3-4-13(20-19-9)10(2)24-16-8-15-11(7-12(16)18)14(21-25-15)5-6-17(22)23/h3-4,7-8,10H,5-6H2,1-2H3,(H,22,23)/t10-/m1/s1 |
| InChIKey | YWASLAPMFGBZQP-SNVBAGLBSA-N |
| SMILES | CC1=NN=C(C=C1)C(C)OC2=C(C=C3C(=C2)ON=C3CCC(=O)O)Cl |
| Reference | [1]. Hutchinson JP, et al. Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Nat Commun. 2017 Jun 12;8:15827. |
